Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q2 2020 · 10-Q
Revenue$189.00K$189.00K+101.1% vs Q2 2019 Net Income-$6.45M-$6.45MN/M vs Q2 2019 EPS Diluted-$0.69-$0.69N/M vs Q2 2019 Operating Income-$6,318,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,422,000N/M Margins · derivedOperating margin-3342.9%+2658.2 pt vs Q2 2019
Net margin-3410.6%+2810.7 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 13, 2020 · 44 d after period end